Committed to the highest global standards of clinical excellence and patient safety, our program adheres rigorously to the quality management protocols required for FACT (Foundation for the Accreditation of Cellular Therapy) and JACIE (Joint Accreditation Committee ISCT-EBMT) accreditations. We are the first hospital in South India to achieve the coveted FACT accreditation, which is a testament to our commitment to quality of care.

Recognizing the complexity of hematological disorders and cellular therapies, our unit operates on a highly integrated model. We deliver seamless, coordinated care through close collaboration with specialized intensive care units, infectious disease experts, transfusion medicine, and dedicated adult and pediatric subspecialists. This multidisciplinary framework ensures holistic clinical support throughout the pre-transplant evaluation, acute inpatient stay, and long-term post-transplant recovery.

In addition to standard hematological indications, our specialized team of hemato-oncologists has developed significant expertise in utilizing Bone Marrow Transplantation as an innovative intervention for severe, refractory autoimmune disorders. We offer this advanced cellular therapy for conditions such as Multiple Sclerosis (MS), Refractory Rheumatoid Arthritis (RRA), and Systemic Lupus Erythematosus (SLE), particularly for patients who have relapsed following standard treatments. Patients are supported through a rigorous three-to-four-week inpatient admission, ensuring they receive the highest standard of specialized care and monitoring.

Advancing hematological care through scientific research is a core pillar of our institution. We provide our patients with access to novel, cutting-edge therapies through active clinical trials. Furthermore, our unit is deeply engaged with national research networks, including the Hematology Cancer Consortium (HCC) and the Indian Society of Bone Marrow Transplantation (ISBMT) in India. Through these collaborative efforts, we contribute to national registries and investigator-initiated trials to develop evidence-based, locally relevant treatment protocols.